Basit öğe kaydını göster

dc.contributor.authorKarakoyun, Süleyman
dc.contributor.authorGürsoy, Mustafa Ozan
dc.contributor.authorKalçık, Macit
dc.contributor.authorYesin, Mahmut
dc.contributor.authorGündüz, Sabahattin
dc.contributor.authorAstarcıoğlu, Mehmet Ali
dc.contributor.authorBayram, Zübeyde
dc.contributor.authorÇakal, Beytullah
dc.contributor.authorBayam, Emrah
dc.contributor.authorÖzkan, Mehmet
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:41Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:41Z
dc.date.issued2017en_US
dc.identifier.citationKarakoyun, S., Gürsoy, M. O., Kalçık, M., Yesin, M., Gündüz, S., Astarcıoğlu, M. A. … Özkan, M. (2017). The role of protein Z and protein Z-dependent protease inhibitor polymorphisms in the development of prosthetic heart valve thrombosis. The Journal of Heart Valve Disease, 26(4), 460-466.en_US
dc.identifier.issn0966-8519
dc.identifier.urihttps://hdl.handle.net/20.500.12511/905
dc.description.abstractBACKGROUND AND AIM OF THE STUDY: Protein Z (PZ) is a vitamin K-dependent factor that is synthesized mainly by the liver. It acts as an activator of serpin, the protein Z-dependent inhibitor (ZPI), which inhibits factor Xa. The potential role of alterations in protein Z and/or ZPI levels in the pathogenesis of thrombotic and/or hemorrhagic diseases has been previously investigated, but results have been conflicting. The study aim was to evaluate the role of PZ/ZPI polymorphisms in the development of prosthetic valve thrombosis (PVT).METHODS: This prospective, observational cross-sectional study included 50 consecutive patients with PVT [non-obstructive thrombosis (NOT) in 35 patients; obstructive thrombosis (OT) in 15] and 50 consecutive healthy subjects with normally functioning prostheses. gDNA was extracted from ca. 5 × 106 leukocytes, using the QIAamp DNA Mini Kit (Qiagen), according to the manufacturer's recommendations. For mutational analysis, a minisequencing method was employed. Results of the analyses were compared between the PVT and control groups, and also between the OT and NOT subgroups.RESULTS: The frequency of A allele (mutant type) of PZG79A was equal in all PVT patients and in controls. With regards to PZ-A13G polymorphisms, frequency of the mutant G allele was 22% in PVT patients and 19% in controls. Serpina-R67X polymorphism was observed in 8% of PVT patients and 6% of controls. Normal variant CC was present in 47 controls (94%), whereas a heterozygotic mutation (CT) was detected in four PVT patients (8%). Frequency of the ZPI-R67X mutation was significantly higher in patients with OT than in those with NOT (p = 0.041).CONCLUSIONS: The present study was the first to evaluate the potential impact of PZ (PZ-A13G, PZG79A) and ZPI (R-67X, W303X) polymorphisms in the development of PVT. Based on the results of this small observational case-control study, PZ/ZPI polymorphisms do not appear to play an active role in the development of PVT. Hence, further extensive studies are necessary.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProsthetic Heart Valve Thrombosisen_US
dc.subjectProtein Zen_US
dc.subjectDependent Protease Inhibitor Polymorphismsen_US
dc.titleThe role of protein Z and protein Z-dependent protease inhibitor polymorphisms in the development of prosthetic heart valve thrombosisen_US
dc.typearticleen_US
dc.relation.ispartofThe Journal of Heart Valve Diseaseen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalıen_US
dc.authorid0000-0003-0230-6575en_US
dc.identifier.volume26en_US
dc.identifier.issue4en_US
dc.identifier.startpage460en_US
dc.identifier.endpage466en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopusqualityQ3en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster